MIM
INO icon

MetLife Investment Management’s Inovio Pharmaceuticals INO Stock Holding History

MetLife Investment Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,167
Closed -$87.7K – 2833
2024
Q3 		$87.7K Buy
15,167
+8,546
+129% +$70.5K ﹤0.01% 2674
2024
Q2 		$53.5K Buy
+6,621
New +$69.7K ﹤0.01% 2750
2023
Q2 		– Sell
-10,547
Closed -$104K – 2966
2023
Q1 		$104K Buy
10,547
+2,473
+31% +$42.2K ﹤0.01% 2535
2022
Q4 		$151K Sell
8,074
-1,837
-19% -$41.6K ﹤0.01% 2414
2022
Q3 		$205K Buy
9,911
+4,328
+78% +$111K ﹤0.01% 2281
2022
Q2 		$116K Sell
5,583
-3,947
-41% -$111K ﹤0.01% 2651
2022
Q1 		$411K Buy
9,530
+3,441
+57% +$155K ﹤0.01% 1893
2021
Q4 		$365K Buy
6,089
+1,077
+21% +$86.3K ﹤0.01% 1675
2021
Q3 		$431K Sell
5,012
-883
-15% -$88.6K ﹤0.01% 1606
2021
Q2 		$656K Hold
5,895
– – 0.01% 1415
2021
Q1 		$656K Buy
5,895
+368
+7% +$48.4K 0.01% 1373
2020
Q4 		$587K Hold
5,527
– – 0.01% 1405
2020
Q3 		$769K Buy
5,527
+253
+5% +$52.8K 0.01% 1160
2020
Q2 		$1.71M Buy
5,274
+1,401
+36% +$225K 0.02% 791
2020
Q1 		$346K Hold
3,873
– – ﹤0.01% 1416
2019
Q4 		$153K Buy
+3,873
New +$117K ﹤0.01% 2123
2019
Q3 		– Sell
-3,025
Closed -$107K – 2360
2019
Q2 		$107K Hold
3,025
– – ﹤0.01% 2357
2019
Q1 		$135K Hold
3,025
– – ﹤0.01% 2192
2018
Q4 		$145K Hold
3,025
– – ﹤0.01% 2095
2018
Q3 		$202K Hold
3,025
– – ﹤0.01% 2074
2018
Q2 		$142K Hold
3,025
– – ﹤0.01% 2087
2018
Q1 		$171K Hold
3,025
– – ﹤0.01% 1969
2017
Q4 		$150K Buy
+3,025
New +$187K ﹤0.01% 2067

Other funds holding INO

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MetLife Investment Management's INO Position: Q4 2024 in Review

MetLife Investment Management sold out of Inovio Pharmaceuticals (INO) in Q4 2024, closing a stake of 15,167 shares — an estimated $87.7K sold.

MetLife Investment Management first reported a position in INO in Q4 2017 and held it in 23 quarters. The position peaked at $1.71M in Q2 2020. 104 funds tracked by Wall St. Rank hold INO as of Q4 2024.

  • MetLife Investment Management reported no remaining Inovio Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • MetLife Investment Management sold 15,167 Inovio Pharmaceuticals shares in Q4 2024, an estimated $87.7K.
  • MetLife Investment Management first reported a position in Inovio Pharmaceuticals in Q4 2017 and held it in 23 quarters.
  • MetLife Investment Management's Inovio Pharmaceuticals position peaked at $1.71M in Q2 2020.
  • 104 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2024.

Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.